Drugs / RABI-767
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06080789 | Jun 2024 → Dec 2026 expected | acute pancreatitis | Panafina, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RABI-767 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06080789 ↗ |
| Route | Other | “125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection.” NCT06080789 ↗ |